Having an idea begin in the laboratory and become a viable treatment or therapy for patients is a goal for researchers across the Texas Medical Center.
Recently, two TMC member institutions saw their cancer therapies gain the distinction of advancing to commercialization.
Ann Leen, Ph.D., and Juan Vera, M.D., along with their colleagues at the Center for Cell and Gene Therapy at Baylor College of Medicine as well as Texas Children’s Hospital and Houston Methodist, developed a therapy for cancer patients that harnesses the patient’s own immune system to fight cancer. The treatment uses a ‘natural’ T cell response that does not require genetic engineering.
In 2015, the group members formed Marker Therapeutics Inc. to facilitate broader patient access to the therapy. Now, Marker is merging with TapImmune Inc., a Florida-based publicly traded company that develops novel immunotherapies for cancer.
The proposed alliance will enable the researchers to perform “advanced-stage clinical testing” to “realize the goal of making immunotherapy a mainstream therapy for patients,” Leen said in a statement.
The partnership also includes a strategic alliance that involves sponsored research, manufacturing support and advancing early-stage clinical trials at Baylor.
Since 2010, more than 25 companies were created within Baylor College of Medicine to advance research from the lab to commercialization, according to Michael Dilling, director of the Baylor Licensing Group, which helps develop commercial relationships that lead to agreements supporting new products and services from Baylor research.
“Entrepreneurial activity has been increasing at Baylor,” he said. “In Marker’s case, that area of development in cell-based therapy is a hot area, and there is commercial interest.”
Meanwhile, The University of Texas MD Anderson Cancer Center has its own history of establishing companies to advance therapies under development within its institution.
“Houston is an untapped gem in the life sciences universe, and this fits with the way Accelerator approaches things,” said David Schubert, chief operating partner at Accelerator Life Science Partners. “There is a lot of great stuff here, which tends to be really early, but driven by powerhouses like MD Anderson, and I am a big believer of what’s going on here.”
This month, MD Anderson and New York-based investment and management firm Accelerator Life Science Partners launched Magnolia Neurosciences Corp.—a company developing a new class of medicines aimed at helping patients suffering from neurodegenerative conditions, such as Alzheimer’s disease and chemotherapy-induced neuropathy in cancer patients.
Magnolia will develop novel therapeutics based on discoveries made by researchers in MD Anderson’s Therapeutics Discovery division, which includes more than 100 clinicians, researchers and drug discovery scientists working to develop innovative treatment options including small molecules, biologics and cell-based therapies.
“This is a really powerful group and we are excited,” said Ferran Prat, Ph.D., vice president of strategic industry ventures at MD Anderson.
Magnolia received $31 million in Series A funding—its first round of venture capital funding.
“Before, it would have been difficult to get investors, but we have established a good track record and have those connections that are on par with the Stanfords and Harvards of the world,” Prat added.
Magnolia also provides David Schubert, chief operating partner at Accelerator, a chance to further his work in Houston. He served as executive director of the Houston Area Translational Research Consortium at Rice University until 2014 and collaborated with Prat since then to understand how the innovation ecosystem works.
“Houston is an untapped gem in the life sciences universe, and this fits with the way Accelerator approaches things,” he said. “There is a lot of great stuff here, which tends to be really early, but driven by powerhouses like MD Anderson, and I am a big believer of what’s going on here.”
#VAResearchNewsBrief: The American College of Physicians @acpinternists released 4 guidance statements on #breastcancer screening for average-risk women. A researcher from the @VAMinneapolis was part of the guideline committee. @VeteransHealth #VAResearch https://t.co/vR1SDnsteD https://t.co/HHj4DPD7cI
@glenda_webb_ @TeamCJCorrea @astros @OrbitAstros Thanks, Glenda, for sharing this great photo!
The underwater dive memorial, called “Circle of Heroes,” will eventually feature 24 concrete statues representing the men and women in the U.S. Air Force, Army, Coast Guard, Marines and Navy https://t.co/VOvuck7S6s via @MiamiHerald
As researchers work to create therapies to target #AML, safety is one of the critical challenges, according to our Dr. Elias Jabbour: https://t.co/S0Wggy1zlD @TargetedOnc #leusm #endcancer
An afternoon swim is a great way to help your kids stay active during the summer months. Make sure they are safe in the water with these tips from Dr. Katherine Leaming-Van Zandt. https://t.co/pVyiG4Jlk3 #swimming #pediatrics
RT @UTHpromotion: Join @UTexasSPH @ProfKimBaker, DrPH, at the #BlackMaternalHealth Summit in Houston on Aug 29 for #BlackMaternalMentalHeal…
RT @NBTStweets: “We feel an obligation because this has happened in our family…So this is our way to pay it forward…We feel an obligation t…
Take a warm bath 1-2 hours before bedtime to get better sleep, @UTHealth researchers find: https://t.co/Bi53wLDvwU
How our #prehab program is helping patients improve strength, endurance and functional capacity ahead of #cancer treatment: https://t.co/eKBYtRtWN5 @DrNgoHuang #endcancer https://t.co/1YQ2YeRYqA
Our Dr. Farhad Ravandi says combining CAR-Ts and BiTEs could “potentially be very interesting and very effective.” #immunotherapy #endcancer https://t.co/Jo7t9JwP9h
Meet the Army Doctor Who Will Spend Seven Months at the International Space Station https://t.co/0FpePtBHWV via @MilitaryOfficer
CHI St. Luke's Health@CHI_StLukes
Last year, Baylor St. Luke’s became the first in Texas to use the #PulseRider, an innovative device used to treat wide-neck bifurcation aneurysms. And now, our team is one of the first to use WEB, a new device in the treatment of complex #BrainAneurysms: https://t.co/QxomC5ne3w https://t.co/kzOvdKt9zO
Deadly fungal disease may be linked to climate change, study suggests: https://t.co/TKlCyiWWxW
University of Houston@UHouston
RT @Brad_Carpenter: How did I not know this little jewel existed on our @UHouston campus?? Get out and explore your campus today. #CoogLead…
@elephande Thank you for sharing your comment with us. Houston Methodist strives to deliver the highest quality, service and care to all our patients. We would like to discuss this issue with you. Please call 713.441.4100 or visit https://t.co/wPtazimDiv